JP7653429B2 - ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス - Google Patents

ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス Download PDF

Info

Publication number
JP7653429B2
JP7653429B2 JP2022525745A JP2022525745A JP7653429B2 JP 7653429 B2 JP7653429 B2 JP 7653429B2 JP 2022525745 A JP2022525745 A JP 2022525745A JP 2022525745 A JP2022525745 A JP 2022525745A JP 7653429 B2 JP7653429 B2 JP 7653429B2
Authority
JP
Japan
Prior art keywords
amphetamine
composition
compound
unconjugated
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501968A (ja
JP2023501968A5 (https=
Inventor
スヴェン ギュンター，
グオチェン チ，
トラビス ミックル，
Original Assignee
ゼブラ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼブラ セラピューティクス， インコーポレイテッド filed Critical ゼブラ セラピューティクス， インコーポレイテッド
Publication of JP2023501968A publication Critical patent/JP2023501968A/ja
Publication of JP2023501968A5 publication Critical patent/JP2023501968A5/ja
Priority to JP2024208343A priority Critical patent/JP2025023120A/ja
Application granted granted Critical
Publication of JP7653429B2 publication Critical patent/JP7653429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2022525745A 2018-10-29 2020-02-21 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス Active JP7653429B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024208343A JP2025023120A (ja) 2018-10-29 2024-11-29 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862752324P 2018-10-29 2018-10-29
US201962800494P 2019-02-02 2019-02-02
US16/667,807 US11174229B2 (en) 2018-10-29 2019-10-29 D-amphetamine compounds, compositions, and processes for making and using the same
US16/667,807 2019-10-29
PCT/US2020/019146 WO2021086427A1 (en) 2018-10-29 2020-02-21 D-amphetamine compounds, compositions, and processes for making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024208343A Division JP2025023120A (ja) 2018-10-29 2024-11-29 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス

Publications (3)

Publication Number Publication Date
JP2023501968A JP2023501968A (ja) 2023-01-20
JP2023501968A5 JP2023501968A5 (https=) 2023-02-06
JP7653429B2 true JP7653429B2 (ja) 2025-03-28

Family

ID=70328134

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2022525745A Active JP7653429B2 (ja) 2018-10-29 2020-02-21 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2022525742A Active JP7653428B2 (ja) 2018-10-29 2020-02-21 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2024071955A Active JP7830540B2 (ja) 2018-10-29 2024-04-25 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2024208343A Pending JP2025023120A (ja) 2018-10-29 2024-11-29 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2025131588A Pending JP2025163212A (ja) 2018-10-29 2025-08-06 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022525742A Active JP7653428B2 (ja) 2018-10-29 2020-02-21 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2024071955A Active JP7830540B2 (ja) 2018-10-29 2024-04-25 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2024208343A Pending JP2025023120A (ja) 2018-10-29 2024-11-29 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2025131588A Pending JP2025163212A (ja) 2018-10-29 2025-08-06 ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス

Country Status (13)

Country Link
US (4) US11174229B2 (https=)
EP (2) EP4051268A4 (https=)
JP (5) JP7653429B2 (https=)
KR (3) KR20220088727A (https=)
CN (2) CN114746091A (https=)
AU (2) AU2020372736A1 (https=)
BR (2) BR112022008208A2 (https=)
CA (2) CA3158405A1 (https=)
IL (2) IL292496A (https=)
MX (2) MX2022005013A (https=)
PH (2) PH12022551047A1 (https=)
WO (2) WO2021086426A1 (https=)
ZA (2) ZA202204678B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same
CN120131637A (zh) * 2025-05-08 2025-06-13 中国人民解放军海军军医大学 左乙拉西坦在制备抗疲劳的药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500242A (ja) 2003-05-29 2007-01-11 ニュー リバー ファーマシューティカルズ インコーポレイテッド 乱用抵抗性アンフェタミン化合物類
US20100303903A1 (en) 2009-05-26 2010-12-02 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
JP2014521656A (ja) 2011-07-28 2014-08-28 ケムファーム・インコーポレーテッド メチルフェニデート−プロドラッグ、その製造法及び使用法
JP2015535849A (ja) 2012-10-05 2015-12-17 スファエラ ファーマ ピーティーイー リミテッド 新規化合物、それらの合成及びそれらの使用
US20190284166A1 (en) 2016-12-11 2019-09-19 Kempharm, Inc. Methylphenidate-prodrugs, processes of making and using the same
JP2023501967A (ja) 2018-10-29 2023-01-20 ケムファーム， インコーポレイテッド ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02504509A (ja) * 1987-08-07 1990-12-20 ジ・アップジョン・カンパニー 非ペプチド結合を有するレニン抑制ペプチド
DE4234012A1 (de) * 1992-10-09 1994-04-14 Basf Ag Neue Anilinderivate und diese enthaltende Pflanzenschutzmittel
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
US8163701B2 (en) 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents
BR102012004888A2 (pt) 2012-03-05 2013-10-22 Phartrials Pesquisas Farmaceuticas Ltda Associação de um derivado de sulfamato monossubstituído do monossacarídeo natural d-frutose (topiramato) com um anti-depressivo da classe das fenilcetonas (bupropiona) para tratamento de obesidade e das síndromes plurimetabólicas
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
AU2013326850B2 (en) * 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
ITUA20161706A1 (it) * 2016-03-15 2017-09-15 Cyanagen S R L Nuovi coloranti cumarinici e relativi coniugati
US20200114014A1 (en) 2017-04-11 2020-04-16 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Amide and Imide Prodrugs of Amphetamine Compounds and Uses Thereof
US20200109117A1 (en) * 2018-10-02 2020-04-09 ACCESS Association Modified Therapeutic Agent Analogs of Mefenamic Acid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500242A (ja) 2003-05-29 2007-01-11 ニュー リバー ファーマシューティカルズ インコーポレイテッド 乱用抵抗性アンフェタミン化合物類
US20100303903A1 (en) 2009-05-26 2010-12-02 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
JP2014521656A (ja) 2011-07-28 2014-08-28 ケムファーム・インコーポレーテッド メチルフェニデート−プロドラッグ、その製造法及び使用法
JP2015535849A (ja) 2012-10-05 2015-12-17 スファエラ ファーマ ピーティーイー リミテッド 新規化合物、それらの合成及びそれらの使用
US20190284166A1 (en) 2016-12-11 2019-09-19 Kempharm, Inc. Methylphenidate-prodrugs, processes of making and using the same
JP2023501967A (ja) 2018-10-29 2023-01-20 ケムファーム， インコーポレイテッド ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rene Braeckman et al.，Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD，2019 APSARD Annual Meeting , POSTER，2019年01月18日，POSTERS F9，https://zevra.com/wp-content/uploads/APSARD-2019-KMPH-KP415-105-Ped-PK-Poster-2019_0118-FINAL.pdf
Rene Braeckman et al.，Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD，2019 APSARD Annual Meeting Abstract Book，2019年01月18日，F9

Also Published As

Publication number Publication date
BR112022008208A2 (pt) 2022-07-12
US12091386B2 (en) 2024-09-17
US11174229B2 (en) 2021-11-16
NZ787388A (en) 2025-05-02
JP2023501968A (ja) 2023-01-20
JP2024091930A (ja) 2024-07-05
US20240199551A1 (en) 2024-06-20
MX2022005013A (es) 2022-08-10
CA3158404A1 (en) 2021-05-06
AU2020376735A1 (en) 2022-05-12
BR112022008216A2 (pt) 2022-07-12
KR20260025885A (ko) 2026-02-24
CN114746091A (zh) 2022-07-12
US20200131130A1 (en) 2020-04-30
EP4051269A4 (en) 2023-12-27
JP7830540B2 (ja) 2026-03-16
JP2025163212A (ja) 2025-10-28
EP4051268A1 (en) 2022-09-07
EP4051269A1 (en) 2022-09-07
CN114746092A (zh) 2022-07-12
NZ787387A (en) 2025-05-02
US20220064116A1 (en) 2022-03-03
CA3158405A1 (en) 2021-05-06
IL292496A (en) 2022-06-01
JP2023501967A (ja) 2023-01-20
PH12022550996A1 (en) 2023-10-02
PH12022551047A1 (en) 2023-05-03
ZA202204678B (en) 2023-01-25
ZA202204747B (en) 2023-05-31
US20200129497A1 (en) 2020-04-30
WO2021086426A1 (en) 2021-05-06
JP2025023120A (ja) 2025-02-14
MX2022005012A (es) 2022-08-08
US11136295B2 (en) 2021-10-05
IL292497A (en) 2022-06-01
AU2020372736A1 (en) 2022-05-12
EP4051268A4 (en) 2024-01-17
KR20220091508A (ko) 2022-06-30
JP7653428B2 (ja) 2025-03-28
KR20220088727A (ko) 2022-06-28
WO2021086427A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US11505537B2 (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
JP2025023120A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP2010512413A (ja) アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法
WO2018107131A1 (en) Methylphenidate-prodrugs, processes of making and using the same
HK40077785A (en) D-amphetamine compounds, compositions, and processes for making and using the same
HK40078104A (en) D-amphetamine compounds, compositions, and processes for making and using the same
BR122025010953A2 (pt) Compostos de d-anfetamina, composição que compreende os mesmos, kit que compreende a dita composição e uso terapêutico dos ditos compostos
HK40111405A (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
HK40015269A (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
HK40015269B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250317

R150 Certificate of patent or registration of utility model

Ref document number: 7653429

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150